Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire Kaihui Pharmaceutical (Shanghai) Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for CNY 270 million on March 8, 2022. The deal is subject to approval from Porton Pharma Solutions Ltd. (SZSE:300363) and Chempartner Pharmatech Co., Ltd. (SZSE:300149) board. As of March 8, 2022 Chempartner Pharmatech Co., Ltd. (SZSE:300149) and Porton Pharma Solutions Ltd. (SZSE:300363) board approved the deal.

As of December 26, 2022, The terms of deal has revised to CNY 241 million. The first installment of the consideration (including the first payment of the first installment of the consideration and the remaining amount of the first installment of the consideration): the amount is adjusted to CNY 34 million, after deducting the first payment of the first installment of the consideration already paid by Porton Pharma (CNY 16 million), the remaining balance of the first installment consideration is CNY 18 million. Porton Pharma Solutions will pay the remaining amount of the first payment to the agreed account within 5 working days after the conditions stipulated in this supplementary agreement are met.

The third phase of consideration was adjusted to CNY 7 million. Porton Pharma will pay the third installment of the consideration to the agreed account within 6 months after the second installment of the consideration is paid if the conditions stipulated in this supplementary agreement are met.